Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.
Bojar
R A
RA
Department of Microbiology, University of Leeds, Yorkshire, England.
Hittel
N
N
Cunliffe
W J
WJ
Holland
K T
KT
D000152:Acne Vulgaris / Q000188:drug therapy / Q000382:microbiology*; D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents; D001419:Bacteria / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000009:adverse effects / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D011807:Quinolizines / Q000009:adverse effects / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011807:Quinolizines; D004917:Erythromycin; C062127:nadifloxacin